Prognostic value of the nodal yield in oral squamous cell carcinoma: a systematic review and meta-analysis.

IF 2.9 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2023-03-01 DOI:10.1080/14737140.2023.2168648

Jiajia Li, Yubo Xu, Jie Zhang, Shaohai Wang, Xiaoyu Wang, Huayan Guo, Guojun Miao

{"title":"Prognostic value of the nodal yield in oral squamous cell carcinoma: a systematic review and meta-analysis.","authors":"Jiajia Li, Yubo Xu, Jie Zhang, Shaohai Wang, Xiaoyu Wang, Huayan Guo, Guojun Miao","doi":"10.1080/14737140.2023.2168648","DOIUrl":null,"url":null,"abstract":"Objectives: To systematically evaluate the prognostic value of the nodal yield in oral squamous cell carcinoma by meta-analysis.Methods: The meta-analysis was adherence to PRISMA. We searched MEDLINE, Embase, and Cochrane for studies published up to 20 April 2022. We collected evidences from observational studies regarding nodal yield in oral squamous cell carcinoma, and investigated its prognostic value by the routine methods of meta-analysis.Results: From seven studies, there was no significant impact of the lymph node yield on overall survival among patients with oral squamous cell carcinoma cases and <18 lymph nodes (hazard ratio (HR) = 1.019, 95% confidence interval (CI) = 0.786-1.320, p = 0.887), with significant heterogeneity (I2 = 80%). The pooled result indicated that a > 18-lymph node yield was a favorable prognostic factor (HR = 0.786, 95%CI = 0.646-0.956, p = 0.016; I2 = 39%). The lymph node yield was not associated with disease-specific survival (HR = 1.594, 95%CI = 0.996-2.552, p = 0.052; I2 = 81%) or disease-free survival (HR = 1.508, 95%CI = 0.924-2.460, p = 0.100; I2 = 41%).Conclusion: A lymph node yield of ≥18 lymph nodes might be a favorable prognostic factor for the overall survival of patients with oral squamous cell carcinoma.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"23 3","pages":"339-345"},"PeriodicalIF":2.9000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2023.2168648","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: To systematically evaluate the prognostic value of the nodal yield in oral squamous cell carcinoma by meta-analysis.

Methods: The meta-analysis was adherence to PRISMA. We searched MEDLINE, Embase, and Cochrane for studies published up to 20 April 2022. We collected evidences from observational studies regarding nodal yield in oral squamous cell carcinoma, and investigated its prognostic value by the routine methods of meta-analysis.

Results: From seven studies, there was no significant impact of the lymph node yield on overall survival among patients with oral squamous cell carcinoma cases and <18 lymph nodes (hazard ratio (HR) = 1.019, 95% confidence interval (CI) = 0.786-1.320, p = 0.887), with significant heterogeneity (I² = 80%). The pooled result indicated that a > 18-lymph node yield was a favorable prognostic factor (HR = 0.786, 95%CI = 0.646-0.956, p = 0.016; I² = 39%). The lymph node yield was not associated with disease-specific survival (HR = 1.594, 95%CI = 0.996-2.552, p = 0.052; I² = 81%) or disease-free survival (HR = 1.508, 95%CI = 0.924-2.460, p = 0.100; I² = 41%).

Conclusion: A lymph node yield of ≥18 lymph nodes might be a favorable prognostic factor for the overall survival of patients with oral squamous cell carcinoma.

查看原文本刊更多论文

口腔鳞状细胞癌淋巴结的预后价值:一项系统回顾和荟萃分析。

目的:通过荟萃分析，系统评价口腔鳞状细胞癌结量的预后价值。方法:meta分析采用PRISMA的依从性。我们检索了MEDLINE、Embase和Cochrane，检索了截至2022年4月20日发表的研究。我们收集了关于口腔鳞状细胞癌结产率的观察性研究证据，并通过常规的meta分析方法研究了其预后价值。结果:在7项研究中，淋巴结清扫对口腔鳞状细胞癌患者的总生存率无显著影响(2 = 80%)。综合结果显示，> 18个淋巴结增生是一个有利的预后因素(HR = 0.786, 95%CI = 0.646-0.956, p = 0.016;i2 = 39%)。淋巴结产量与疾病特异性生存无相关性(HR = 1.594, 95%CI = 0.996-2.552, p = 0.052;I2 = 81%)或无病生存期(HR = 1.508, 95% ci -2.460 = 0.924, p = 0.100;i2 = 41%)。结论:淋巴结≥18个淋巴结可能是口腔鳞状细胞癌患者总体生存的有利预后因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.